Kalaora et al. demonstrated a correlation between elevated expression of PSMB8 and PSMB9 with heightened responsiveness to anti-CTLA4 and anti-PD1 therapies and improved survival rates in melanoma patients [167]. Here, CTLA4 is linked to melanoma.